Table 2 Multivariate analysis of relapse... | American Society of Hematology

Table 2

Multivariate analysis of relapse and disease-free survival

	AML patient transplantations
	n	Relapse			Disease-free survival
	n	RR of relapse	95% CI	P	RR of relapse or death	95% CI	P
*Donor KIR: A/A* and B/x genotypes**
Donor KIR genotype
KIR-A/A	362	1.00			1.00
KIR-B/x	696	0.72	0.58-0.89	.003	0.85	0.73-0.99	.04
*Donor KIR: centromeric and telomeric genotypes*
Donor Cen genotype
Cen-A/A	516	1.00			1.00
Cen-A/B	427	0.87	0.70-1.09	.20	0.94	0.81-1.10	.45
Cen-B/B	115	0.34	0.20-0.57	< .001	0.72	0.55-0.93	.01
Cen-B/A vs Cen-B/B				< .001			.04
*Donor Tel* genotype**
Tel-A/A	643	1.00			1.00
Tel-A/B	371	0.70	0.56-0.89	.003	0.87	0.74-1.02	.08
Tel-B/B	44	0.52	0.26-1.06	.07	0.82	0.55-1.20	.32
Tel-A/B vs Tel-B/B				.45			.77
*Donor KIR B–content score*
Donor KIR B motifs
0	364	1.00			1.00
1	366	0.93	0.73-1.19	.56	0.94	0.79-1.11	.45
2	242	0.54	0.39-0.74	< .001	0.77	0.63-0.94	.01
3 or 4	86	0.44	0.27-0.73	< .001	0.76	0.56-1.01	.06
*Donor KIR: B–content group*
KIR B = 0 or 1	730	1.00			1.00
B ≥ 2 (Cen-A/x, Tel-B/x)	213	0.64	0.48-0.86	.003	0.84	0.70-1.01	.07
B ≥ 2 (Cen-B/B, Tel-x/x)	115	0.33	0.20-0.55	< .001	0.70	0.55-0.90	.007
*Donor KIR* genotype and HLA match**
HLA-matched
B = 0 or 1	374	1.00			1.00
B ≥ 2	165	0.52	0.36-0.75	< .001	0.80	0.62-1.02	.07
HLA-mismatched
B = 0 or 1	374	1.00			1.00
B ≥ 2	173	0.52	0.35-0.75	< .001	0.78	0.63-0.97	.03
Disease status and HLA match
Disease status
Early	286	1.00			1.00
Intermediate	341	1.51	1.01-2.26	.044	1.47	1.13-1.90	.005
Advanced	431	2.99	2.25-3.98	< .001	2.38	1.94-2.92	< .001
HLA match
10/10	539	1.00			1.0
Less than 10/10	547	0.94	0.88-1.17	.57	1.30	1.12-1.51	< .001

	AML patient transplantations
	n	Relapse			Disease-free survival
	n	RR of relapse	95% CI	P	RR of relapse or death	95% CI	P
*Donor KIR: A/A* and B/x genotypes**
Donor KIR genotype
KIR-A/A	362	1.00			1.00
KIR-B/x	696	0.72	0.58-0.89	.003	0.85	0.73-0.99	.04
*Donor KIR: centromeric and telomeric genotypes*
Donor Cen genotype
Cen-A/A	516	1.00			1.00
Cen-A/B	427	0.87	0.70-1.09	.20	0.94	0.81-1.10	.45
Cen-B/B	115	0.34	0.20-0.57	< .001	0.72	0.55-0.93	.01
Cen-B/A vs Cen-B/B				< .001			.04
*Donor Tel* genotype**
Tel-A/A	643	1.00			1.00
Tel-A/B	371	0.70	0.56-0.89	.003	0.87	0.74-1.02	.08
Tel-B/B	44	0.52	0.26-1.06	.07	0.82	0.55-1.20	.32
Tel-A/B vs Tel-B/B				.45			.77
*Donor KIR B–content score*
Donor KIR B motifs
0	364	1.00			1.00
1	366	0.93	0.73-1.19	.56	0.94	0.79-1.11	.45
2	242	0.54	0.39-0.74	< .001	0.77	0.63-0.94	.01
3 or 4	86	0.44	0.27-0.73	< .001	0.76	0.56-1.01	.06
*Donor KIR: B–content group*
KIR B = 0 or 1	730	1.00			1.00
B ≥ 2 (Cen-A/x, Tel-B/x)	213	0.64	0.48-0.86	.003	0.84	0.70-1.01	.07
B ≥ 2 (Cen-B/B, Tel-x/x)	115	0.33	0.20-0.55	< .001	0.70	0.55-0.90	.007
*Donor KIR* genotype and HLA match**
HLA-matched
B = 0 or 1	374	1.00			1.00
B ≥ 2	165	0.52	0.36-0.75	< .001	0.80	0.62-1.02	.07
HLA-mismatched
B = 0 or 1	374	1.00			1.00
B ≥ 2	173	0.52	0.35-0.75	< .001	0.78	0.63-0.97	.03
Disease status and HLA match
Disease status
Early	286	1.00			1.00
Intermediate	341	1.51	1.01-2.26	.044	1.47	1.13-1.90	.005
Advanced	431	2.99	2.25-3.98	< .001	2.38	1.94-2.92	< .001
HLA match
10/10	539	1.00			1.0
Less than 10/10	547	0.94	0.88-1.17	.57	1.30	1.12-1.51	< .001

AML indicates acute myelogenous leukemia; 95% CI, 95% confidence interval; HLA, human leukocyte antigen; and RR, relative risk.